LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Raaxo takes shape after pivot from Aphrodite Bra Co’s body scan concept
Despite its use of body-mapping technology, Aphrodite Bra Company wasn’t the right fit for customers’ needs, said Carlanda McKinney, founder of the newly rebooted custom intimates company Raaxo. “Aphrodite had been stuck in the starting-up space,” she said. “We’d never really gotten enough sales or enough traction to say, ‘We’re launched,’ or, ‘We’re in business.’…
Serial entrepreneur leverages past success for Bridge Space coworking project
Bridge Space will be more than a coworking office, Ben Rao said. He hopes it will be the heart of Lee’s Summit’s blossoming entrepreneurial ecosystem. “My No. 1 goal is to accelerate entrepreneurs’ success,” said Rao, Bridge Space founder and a serial entrepreneur himself. “It’s an opportunity for me to build something that would make…
KC mom’s humble entrepreneurial journey draws on healing power of creativity
Huddled in her parents’ basement, between the cribs of her crying twin babies, Keliah Smith began to draw. She was unemployed and feeling emotionally drained. The relationship with her children’s father had soured. Her escape: the stylus and smartphone in her hands. The Kansas City mother drew what she didn’t see in the mirror, she…
Harvard University recognizes KCMO digital inclusion map
Kansas City’s geographic work to illustrate the area’s digital divide earned high praise from a prestigious university. Harvard University recently highlighted the City of Kansas City, Missouri’s Digital Inclusion map, a tool that — at a block-by-block scale — detail residents’ access to internet connectivity overlaid with poverty levels. “This visualization was chosen as Harvard’s…